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Abstract:
Background: Preterm birth remains a common cause of neonatal mortality with a
disproportionate burden occurring in low and middle-income countries. Meta-analyses of lowdose aspirin to prevent preeclampsia suggest that the incidence of preterm birth may be
decreased, particularly if initiated before 16 weeks.
Methods: We conducted a multi-country randomized, double masked trial of aspirin (81 mg)
daily compared to placebo initiated between 6 weeks and 0 days of pregnancy and 13 weeks
and 6 days of pregnancy in nulliparous women. Prior to randomization, ultrasound confirmed the
gestational age and presence of a singleton viable pregnancy. The primary outcome was
preterm birth, defined as delivery at or after 20 weeks and prior to 37 weeks gestational age.
Results: A total of 11,976 women in 6 countries (India, Guatemala, Pakistan, Kenya, Zambia,
Democratic Republic of Congo) were randomly assigned to aspirin (5,990 women) or placebo
(5,986 women). Preterm birth occurred in 11.6% of women randomized to aspirin and 13.1%
randomized to placebo (RR, 0.89; 95% CI, 0.81 to 0.98). Women who took aspirin were also
less likely to deliver before 34 weeks gestation (3.3% vs 4.0%; RR, 0.75; 95%CI, 0.61 to 0.93)
or experience perinatal mortality (45.7/1000 vs 53.6/1000; RR, 0.86; 95%CI, 0.73 to 1.00).
Adverse maternal events were similar between the two groups.
Conclusions: In nulliparous women with singleton pregnancies, low dose aspirin initiated
between 6 weeks and 0 days and 13 weeks and 6 days results in lower rates of preterm delivery
before 37 weeks and before 34 weeks.
Trial Registration: Funded by the Eunice Kennedy Shriver National Institute of Child Health
and Human Development; NCT ASPIRIN ClinicalTrials.gov 02409680/Clinical Trials RegistryIndia CTRI/2016/05/006970.
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Background:
Preterm birth, defined as delivery prior to 37 weeks, remains a predominant driver of infant
mortality worldwide with the greatest burden of disease occurring in low and middle-income
countries1,2. Though improvements in neonatal care have resulted in improved survival3, this
care is often limited or unavailable in the regions with the highest burden of mortality. Beyond
the newborn period, longitudinal adverse effects in health and socioeconomic outcomes have
been associated with preterm delivery compared to individuals delivered at term4–6. Despite
numerous trials of preventive and tocolytic therapies, an effective strategy for the prevention of
preterm birth has proved elusive, beyond a few at-risk groups7,8.
Meta-analyses and systematic reviews of trials of low-dose aspirin in pregnant women for the
purpose of prevention of preeclampsia have suggested that women receiving aspirin have a
lower occurrence of preterm birth9–12. This effect may be greater when low dose aspirin is
begun before 16 weeks of gestation13. Though promising as a strategy, a large definitive trial of
low-dose aspirin initiated early in pregnancy with the prevention of preterm birth as the primary
outcome has not been conducted. The Aspirin (Aspirin Supplementation for Pregnancy
Indicated risk Reduction In Nulliparas-ClinicalTrials.gov Identifier: NCT02409680/Clinical Trials
Registry-India CTRI/2016/05/006970) trial was therefore designed to test the hypothesis that
low-dose aspirin (81 mg) administered daily initiated between 6 weeks 0 days and 13 weeks 6
days reduces the incidence of preterm delivery amongst nulliparous women with a singleton
pregnancy.
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Trial Oversight:
We conducted a multinational, randomized double-masked, placebo-controlled trial assessing
daily low- dose aspirin (81 mg) begun between 6 weeks and 0 days and 13 weeks and 6 days
until 36 weeks and 0 days of pregnancy to prevent preterm birth before 37 weeks amongst
nulliparous women with a singleton pregnancy. Nulliparous women were selected as they have
a higher rate of preterm birth than multiparous women14 and are unlikely to undergo treatment to
prevent prematurity due to a lack of obstetrical history. The trial was conducted by the NICHD
Global Network for Women’s and Children’s Health Research in 7 sites in 6 countries- India (2
sites), Pakistan, Zambia, Democratic Republic of Congo, Guatemala and Kenya - between
March 2016 and April 2019. The trial protocol (available with the full text of this article at
NEJM.org) has been previously published15. Prior to the initiation of the trial, the protocol was
approved by the relevant ethics committees and regulatory agencies of each country as well as
the ethics committees of the United States-based collaborators and that of the Research
Triangle Institute (RTI) International. The trial was conducted in accordance with Good Clinical
Practice Guidelines. An external independent data and safety monitoring board oversaw the
conduct of the trial and monitored the occurrence of serious adverse events. No formal interim
analyses were planned nor conducted.
Trial initiation, data management, safety monitoring, drug/placebo supply procurement, and
supply chain management, as well as development of the statistical plan and performance of
the analyses were performed by the trial’s data coordinating center, RTI International. The trial
protocol and the manuscript were written by the lead author, trial statisticians, and members of
the steering committee (NICHD representatives, RTI International researchers and site research
representatives). All authors attest to the accuracy and completeness of the data and the
fidelity of the trial to the protocol.
Screening and recruitment:
Each site established a plan to screen pregnant women residing within the study communities.
Nulliparous women between 6 weeks and 0 days and 13 weeks and 6 days, who were between
14 (18 when required by individual ethics boards) and 40 years of age, were identified and were
individually consented for participation by trained staff. We excluded women who had any of
the following by medical history: allergy or contraindication to aspirin, previously taken aspirin
therapy for more than 7 days during this pregnancy, multiple gestations, history of more than
two first trimester losses, or medical conditions for which low-dose aspirin therapy is currently
indicated (e.g. diabetes and hypertension). Non-excluded women then underwent a medical
screening for additional eligibility criteria which included: blood pressure (BP > 140/90 were
excluded), hemoglobin assessment (<7.0 g/dl were excluded) and ultrasound for gestational
age dating. Women were also excluded from the trial if the ultrasound demonstrated absence
of a fetal heartbeat, multiple gestations, and/or presence of a fetal anomaly. The crown-rump
length and last menstrual period were entered into a smartphone application to determine the
gestational age in accordance with American College of Obstetrics and Gynecology (ACOG)
guidance16.
Randomization and trial regimen:
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Eligible and consented women were randomly assigned in a 1:1 ratio to a daily regime of either
81 mg of aspirin or placebo. The aspirin tablets and placebo were manufactured by Morepen
Laboratories in Parwanoo, Himachal Pradesh, India and Helix Pharma Limited located in
Karachi, Pakistan. Packaging and distribution were handled by Bilcare Research Global Clinical
Supplies. The placebo tablets were identical to the aspirin tablets in size, weight, and
appearance. Certificates of analysis following USP reference standards were performed for
each lot produced. Stability testing at 6, 12, 18, and 24 months for each lot was performed by
high performance liquid chromatography for active ingredients and appearance by RTI
International. The randomization sequence was developed for each site by the data
coordinating center using a computer algorithm based on randomly permuted block design with
varied block sizes. Women then received sequentially numbered pre-packaged 2-week
medication allotments. These were exchanged every 2 weeks by study personnel and an
assessment of compliance, side-effects, interval medical contacts, and concomitant medications
were documented. Throughout the study, research staff and local health providers were masked
to treatment. Blood pressure assessments were made between 16 to 20 weeks, 28 to 30
weeks and then biweekly beginning at 34 weeks until delivery. Repeat hemoglobin assessments
were obtained between 26-30 weeks. Maternal and neonatal outcomes were obtained through
42 days using a previously described registry 17.
Outcomes:
The primary outcome of this study was preterm birth, which was defined as any delivery at or
after 20 weeks 0 days and prior to 37 weeks and 0 days. Predefined secondary maternal
outcomes were hypertensive disorders of pregnancy, preterm (<34 weeks’ gestation)
hypertensive disorders of pregnancy, vaginal bleeding, antepartum hemorrhage, postpartum
hemorrhage, maternal mortality through 42 days postpartum, and late abortion. Secondary
fetal/neonatal outcomes were perinatal mortality, preterm birth before 34 weeks, preterm birth
before 28 weeks, small for gestational age as defined by the Intergrowth standard18, birthweight
<1500 gm, birthweight <2500 gm, spontaneous abortion, stillbirth (both non-macerated and total
stillbirth), fetal loss (defined as birth between 16-20 weeks and perinatal mortality between 20
weeks to <7 days post-delivery), and medical termination of pregnancy. All staff were trained in
the study procedures, and methods of internal quality checks were designed to ensure high
quality data. Definitions of secondary outcomes are provided in the Supplementary Appendix.
Review of outcomes and data consistency was performed in a masked fashion prior to data lock
and analysis. Quality assessment of the ultrasound images was performed contemporaneously
on 10% of studies with feedback provided to the individual sonographer.
Statistical Analysis:
The expected incidence of the primary outcome was conservatively estimated to be 8%1.
Assuming a 5% risk of miscarriage and a 2% rate of lost to follow up, the sample size of 11,920
participants (5,960 per arm) would provide 90% power to detect a 20% reduction in the
incidence of preterm birth in women treated with low-dose aspirin assuming a two-sided type
one error of 5%. Recognizing that missing data was likely to occur due to miscarriage and/or
medical termination of pregnancy, we planned a priori to perform a modified intent to treat
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analysis for the primary outcome including only women who achieved a pregnancy of 20 weeks
and beyond (See the Supplementary Appendix). Women who were subsequently determined to
be ineligible were excluded from the analysis as part of the modified intent to treat approach.
We also pre-specified a sensitivity analysis within a per-protocol population, defined primarily as
a participant who consumed 90% of her prescribed regimen (See the Supplementary Appendix).
Analyses of all binary outcomes included a Cochran-Mantel-Haenszel test stratified by site to
formally test the primary hypothesis followed by generalized linear model-based sensitivity
analyses that explore the treatment by site interaction, adjustment for key demographic, and
clinical variables. Analyses of secondary outcomes are exploratory in nature and therefore, pvalues and confidence intervals are provided for descriptive purposes only and no adjustment
for multiple comparisons were made. Serious adverse events were assessed on all women who
were allocated to drug or placebo (safety population). Further description of the statistical
methods is provided in the Supplementary Appendix.
Results:
Characteristics of the participants:
From March 2016 through June 2018, a total of 14361 women underwent screening for eligibility
after providing informed consent. A total of 2385 women were excluded or declined
randomization and the remaining 11976 consented and were randomized: 5990 were assigned
to low-dose aspirin and 5986 were allocated to placebo (Figure 1). The low-dose aspirin group
had 5787 women who were in the modified intent to treat (MITT) population and the placebo
group contained 5771. Baseline characteristics and site of delivery were similar between the
two groups (Table 1). Overall adherence to medication or placebo defined as taking > 90% of
the prescribed medications was high (MITT population overall 84.9%: aspirin 85.3% vs placebo
84.4%). The quality of the drug was evaluated upon manufacture and episodic assessments of
stability by a masked third party demonstrated appropriate potency throughout the duration of
the study (See the Supplementary Appendix).
Primary outcome
The primary outcome of preterm delivery before 37 weeks occurred in 11.6% of women
receiving aspirin and 13.1% of women in the placebo group (RR, 0.89; 95%CI, 0.81 to 0.98). To
prevent one preterm delivery, 66 women (NNT) would need to be prescribed aspirin. In the per
protocol population, the primary outcome occurred in 10.9% of women receiving aspirin and
12.3% of women in the placebo group (RR, 0.89; 95% CI, 0.80 to 0.99). No interaction between
the study site and the primary outcome was seen in either of these analyses. The intent to treat
outcomes are noted to be similar to the modified intent to treat analyses and are provided in the
Supplementary Appendix.
Secondary outcomes
Preterm delivery before 34 weeks was reduced in women who were randomized to aspirin
compared to those randomized to placebo (3.3% vs. 4.0%; RR, 0.75; 95%CI, 0.61 to 0.93).
Preterm delivery before 28 weeks trended lower in women who received aspirin compared to
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placebo but did not achieve statistical significance (0.9% vs. 1.3%; RR, 0.72; 95%CI, 0.51 to
1.02). Perinatal mortality occurred less frequently among women randomized to aspirin
compared to those who received placebo (aspirin 45.7/1000 vs placebo 53.6/1000; RR, 0.86;
95%CI, 0.73 to 1.00). The incidence of overall hypertensive disorders of pregnancy was not
different between women randomized to aspirin (6.1%) and those who received placebo (5.6%)
(RR, 1.08; 95%CI, 0.94 to 1.25); however, the incidence of women who were delivered before
34 weeks with hypertensive disorders of pregnancy was significantly lower in women
randomized to aspirin (0.1%) compared to women randomized to placebo (0.4%)(RR, 0.38;
95%CI, 0.17 to 0.85). No differences in the occurrence of fetal growth abnormalities defined as
a birthweight <2500 gm or <1500 gm were noted between the two groups (Table 2). Fetal loss
(Stillbirth and abortion at or after 16 weeks) was also lower among women randomized to
aspirin (52.1/1000) compared to women who received placebo (60.8/1000)(RR, 0.86; 95% CI,
0.74 to 1.00) Other maternal and fetal/neonatal outcomes were similar between the two groups.
Maternal and Fetal/Neonatal Serious Adverse Events
Overall serious adverse events were similar between the groups (aspirin 14.0% vs placebo
14.4%- RR, 0.94; 95%CI, 0.84 to 1.05). Broad categories of adverse events are compared
between groups and are shown in table 3A (maternal) and 3B (fetal/neonatal). No differences in
maternal bleeding complications (antepartum hemorrhage, postpartum hemorrhage, or upper
gastrointestinal bleeding) were detected between the groups. The proportion of women who had
a second hemoglobin < 7.0 g/dl or had a 3.5 g/dl drop also did not differ between groups.
Maternal mortality was high (176/100000) compared to high-income countries, though no
observable differences were seen between groups. Fetal/neonatal serious adverse events did
not differ between women who received aspirin and those who received placebo. No differences
were seen in the rates of overall anomalies, gastroschisis or neonatal death.
Discussion
In this randomized double masked controlled trial, nulliparous women with a singleton
pregnancy who were allocated to low-dose aspirin between 6 weeks and 0 days and 13 weeks
and 6 days until 36 weeks gestation were 11% less likely to deliver before 37 weeks. Similarly,
the risk of preterm delivery prior to 34 weeks was lowered by 25% and perinatal mortality was
decreased by 16%. Importantly, we saw no increase in either maternal or fetal serious adverse
events between women prescribed low-dose aspirin compared to women who received placebo.
These outcomes are consistent with several meta-analyses which had demonstrated similar
levels of reduction of preterm birth and perinatal mortality 9,19,20 . Because of the large sample
size, this trial was able to demonstrate these benefits definitively in a diverse group of women in
six low and middle- income countries. The simple eligibility criteria used as part of this trial
allows this intervention to potentially be applied to diverse groups of pregnant women in multiple
settings and may be particularly relevant in low- and middle-income countries. The low cost and
demonstrated tolerability of aspirin in this population suggests that this intervention can be
readily and safely adopted across a span of clinical sites.
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Several limitations should be noted. First the applicability of this intervention to other groups of
women beyond nulliparas with singleton gestations remains unclear. Secondly, prior metaanalyses have suggested that higher doses of aspirin (>100 mg) may further lower the
incidence of preeclampsia10. The optimal dose and time of initiation for the prevention of
preterm birth remains unclear. Finally, though aspirin has been endorsed for the prevention of
preeclampsia at term, we were only able to demonstrate a decrease in the incidence of preterm
(<34 weeks) hypertensive disorders of pregnancy. This failure to demonstrate a difference in
term preeclampsia may be related to both our definition of hypertensive disorders of pregnancy
and the settings in which we performed this study. The diagnosis of preeclampsia most
commonly occurs at the time of the birth admission. In the care settings for this trial,
measurement of blood pressure and assessment of proteinuria does not routinely occur,
potentially leading to an ascertainment bias. Recognizing this challenge in our care settings, we
chose to use an expansive diagnosis of hypertensive disorders (See the Supplementary
Appendix) that may have led to imprecision in this outcome. Nonetheless, our trial of aspirin in
pregnancy is similar to other large trials that have likewise failed to demonstrate a benefit in the
decreasing in the incidence of preeclampsia at term but noted effects earlier in pregnancy21–23 .
In conclusion, this trial demonstrates that the administration of aspirin at a dose of 81 mg
beginning between 6 weeks 0 days and 13 weeks 6 days through 36 weeks resulted in a
significantly lower incidence of preterm birth amongst women with a singleton pregnancy in low
and middle-income countries.
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Figure 1. Randomization and Follow-up in the ASPIRIN Trial

Enrollment

Assessed for eligibility (n=14,361)

Excluded (n=2,385)


Not meeting inclusion criteria (n=1,534)
 Declined to participate (n=157)
 Did not complete screening process (n=694)

Randomized (n=11,976)

Allocation

Allocated to Aspirin (n=5,990)
 Received allocated intervention (n=5,943)

Allocated to Placebo (n= 5,986)
 Received allocated intervention (n=5,936)





Did not receive allocated intervention due to
early loss pregnancy loss or did not take any
study medication (n=47)
Lost to follow-up (n=15)
 Lost to follow-up prior to delivery (n=15)
 Mother lost to follow-up prior to 42 days (n=1)
 Infant lost to follow-up prior to 42 days (n=4)

Follow-Up

Discontinued intervention (n=89)
 Withdrew consent (n=51)
 Participant moved away from study area (n=20)
 Investigator terminated participant (n=18)

Did not receive allocated intervention due to
early pregnancy loss or did not take any study
medication (n=50)
Lost to follow-up (n=30)
 Lost to follow-up prior to delivery (n=30)
 Mother lost to follow-up prior to 42 days (n=1)
 Infant lost to follow-up prior to 42 days (n=4)
Discontinued intervention (n=69)
 Withdrew consent (n=33)
 Participant moved away from study area (n=21)
 Investigator terminated participant (n=15)

Analysis
Analysed: Modified Intent to Treat (n=5,787)
 Excluded from analysis (n=203)
 Ineligible participants (n=16)
 Lost to follow-up prior to delivery (n=15)
 Pregnancy outcome < 20 weeks (n=172)
Analysed: Intent to Treat (n=5,974)
 Excluded from analysis (n=16)
 Ineligible participants (n=16)

Analysed: Modified Intent to Treat (n=5,771)
days (n=1)

 Mother
lost to
follow-up
prior
to 42
 Excluded
from
analysis
(n=215)


Ineligible participants (n=7)
Lost to follow-up prior to delivery (n=30)
 Pregnancy outcome < 20 weeks (n=178)
Analysed: Intent to Treat (n=5,979)
 Excluded from analysis (n=7)
 Ineligible participants (n=7)
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Table 1. Baseline and Site of Delivery Characteristics (Intent to Treat Population)
Characteristic

Aspirin

Placebo

Modified Intent to Treat Population

5,974

5,979

< 20

2,320 (38.8)

2,357 (39.4)

20 – 29

3,523 (59.0)

3,487 (58.3)

131 (2.2)

135 (2.3)

10.0 (8.6,

10.1 (8.6,

12.0)

12.0)

No formal schooling

875 (14.6)

872 (14.6)

1-6 years of schooling

876 (14.7)

888 (14.9)

7-12 years of schooling

3,574 (59.8)

3,567 (59.7)

≥ 13 years of schooling

648 (10.8)

651 (10.9)

Maternal height (cm), Mean (StdDev)

153.2 (6.9)

153.1 (7.0)

Maternal weight (Kg), Mean (StdDev)

49.3 (9.0)

49.2 (8.7)

Maternal BMI (Kg/m2), Mean (StdDev)

21.1 (3.8)

21.0 (3.7)

5 (4, 6)

5 (4, 6)

Physician

2,990 (50.2)

2,962 (49.8)

Nurse/Nurse midwife

2,284 (38.4)

2,277 (38.3)

Maternal age (years), n (%)

> 29
Projected gestational age at enrollment (weeks), Median
(P25, P75)
Maternal education, n (%)

Antenatal care visits, Median (P25, P75)
Delivery attendant, n (%)
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Characteristic

Aspirin

Placebo

Traditional birth attendant

472 (7.9)

476 (8.0)

Family/Self/Other

208 (3.5)

229 (3.9)

Hospital

3,541 (59.5)

3,554 (59.8)

Clinic/Health center

1,854 (31.1)

1,798 (30.2)

561 (9.4)

594 (10.0)

Vaginal

4,278 (71.8)

4,348 (73.1)

C-Section

1,523 (25.6)

1,441 (24.2)

Miscarriage

114 (1.9)

131 (2.2)

MTP

41 (0.7)

26 (0.4)

Delivery location, n (%)

Home/Other
Delivery mode, n (%)

Characteristics were compared between study arms using chi-square tests for categorical
measures, t-tests for continuous data, and Wilcoxon rank sum tests for ordinal data. All p-values
comparing treatment groups were greater than 0.05.
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Table 2. Primary, Secondary, and Other Outcomes
Outcome

Aspirin

Placebo

p-Value4

RR (95% CI)5

668/5,780

754/5,764 (13.1)

0.012

0.89 (0.81, 0.98)

352/5,780 (6.1) 325/5,764 (5.6)

0.30

1.08 (0.94, 1.25)

0.17

0.95 (0.90, 1.01)

Primary Outcome
Preterm delivery1, n/N (%)

(11.6)
Secondary Efficacy Outcomes
Hypertensive disorders1, n/N (%)
Small for gestational age1, n/N (%)

1,506/5,492

1,564/5,467

(27.4)

(28.6)

264/5,779

309/5,763 (53.6)

0.048

0.86 (0.73, 1.00)

Vaginal bleeding2, n/N (%)

214/5,933 (3.6) 246/5,940 (4.1)

0.13

0.87 (0.73, 1.04)

Antepartum hemorrhage1, 6, n/N (%)

26/5,761 (0.5)

25/5,746 (0.4)

0.90

1.03 (0.60, 1.79)

Postpartum hemorrhage3, 6, n/N (%)

54/5,928 (0.9)

43/5,907 (0.7)

0.27

1.25 (0.84, 1.86)

Maternal mortality through 42 days2, 6,

9/5,958 (151)

12/5,948 (202)

0.51

0.75 (0.32, 1.78)

Late abortion2, n/N (Rate/1000)

23/5,819 (4.0)

30/5,808 (5.2)

0.33

0.77 (0.45, 1.31)

Preterm and hypertensive disorders1, 6, n/N

8/5,780 (0.1)

21/5,764 (0.4)

0.015

0.38 (0.17, 0.85)

Preterm < 34 weeks of pregnancy1, n/N (%) 189/5,780 (3.3) 230/5,764 (4.0)

0.039

0.75 (0.61, 0.93)

Perinatal mortality1, n/N (Rate/1000)

(45.7)
Other Maternal Outcomes of Interest

n/N (Rate/100,000 deliveries)

(%)
Other Fetal Outcomes of Interest
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Outcome
Preterm < 28 weeks of pregnancy1, n/N (%)
Measured birth weight < 2500g1, n/N (%)

Birth weight < 2500g1, 7, n/N (%)

Aspirin

Placebo

p-Value4

RR (95% CI)5

54/5,780 (0.9)

75/5,764 (1.3)

0.06

0.72 (0.51, 1.02)

1,078/5,628

1,153/5,624

0.07

0.93 (0.87, 1.01)

(19.2)

(20.5)

1,101/5,671

1,178/5,671

0.07

0.94 (0.87, 1.01)

(19.4)

(20.8)

Measured birth weight < 1500g1, 7, n/N (%)

78/5,628 (1.4) 101/5,624 (1.8)

0.08

0.87 (0.57, 1.33)

Birth weight < 1500g1, n/N (%)

97/5,671 (1.7) 118/5,671 (2.1)

0.15

0.79 (0.58, 1.07)

353/5,807 (60.8)

0.039

0.86 (0.74, 1.00)

152/5,946 (25.6)

0.26

0.88 (0.70, 1.10)

119/5,717 (20.8)

0.32

0.88 (0.68, 1.14)

166/5,764 (28.8)

0.14

0.85 (0.68, 1.06)

30/5,946 (5.0)

0.16

1.40 (0.88, 2.23)

Fetal loss2,8, n/N (Rate/1000)

303/5,818
(52.1)

Spontaneous abortion2, n/N (Rate/1000)

134/5,956
(22.5)

Stillbirth (macerated excluded)1, n/N
(Rate/1000)
All Stillbirth1, n/N (Rate/1000)

105/5,744
(18.3)
141/5,780
(24.4)

Medical termination of pregnancy (MTP) 2, 6, 42/5,956 (7.1)
n/N (Rate/1000)

Note: The following superscripts indicate the analysis population for each outcome variables:1 Modified intent to treat
(mITT), 2 Intent to treat (ITT) and 3 Safety.
4

P-values from Cochran-Mantel-Haenszel tests stratified by site.
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5

P-values for treatment by site interaction obtained from binomial models with a log link adjusting for site, treatment
and site by treatment interaction. If treatment by site interaction term is significant (p < 0.05), then the relative risk and
95% confidence interval are obtained from a binomial model with a log link adjusting for site, treatment and site by
treatment interaction and is based on the average effect across sites. If the interaction term is not significant then the
relative risk and 95% confidence interval are obtained from a binomial model with a log link adjusting for site and
treatment.
6

Antepartum hemorrhage, postpartum hemorrhage, maternal mortality < 42 days, preterm and hypertensive disorders
and MTP have low or zero cell counts for at least one site and treatment combination. For these outcomes the relative
risks are from models adjusting for site and treatment.
7

Data from women with Birth weight missing (N=26) or measured after 4 days are excluded (N=84). 90 babies have
only estimated weight and 76% of stillbirths have measured birth weight.
8

Fetal loss is defined as any death of an infant greater than 16 weeks GA and prior to 7 days post-delivery. Any fetal
loss (including termination of pregnancy or miscarriage) that occurs prior to 16 weeks is excluded.
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Table 3. Serious Adverse Events
pEvents

Aspirin

Placebo

RR (95% CI)1
Value1

Safety population, N

5,943

5,936

832 (14.0)

857 (14.4)

0.94 (0.84, 1.05)

0.25

495 (8.3)

514 (8.7)

0.97 (0.86, 1.09)

0.58

Maternal death, n (%)

9 (0.2)

12 (0.2)

0.75 (0.32, 1.78)

0.51

Vaginal spotting/Bleeding/Leaking pv2,

10 (0.2)

10 (0.2)

1.00 (0.42, 2.39)

1.0

Antepartum hemorrhage, n (%)

35 (0.6)

33 (0.6)

1.06 (0.66, 1.70)

0.82

Postpartum hemorrhage, n (%)

50 (0.8)

43 (0.7)

1.24 (0.42, 3.63)

0.70

Anemia/Drop in Hb > 3.5 g/dl2, n (%)

24 (0.4)

23 (0.4)

1.04 (0.59, 1.84)

0.89

Preeclampsia/Eclampsia, n (%)

150 (2.5)

141 (2.4)

1.06 (0.85, 1.33)

0.59

Preterm labor/Preterm birth evaluation

45 (0.8)

56 (0.9)

0.80 (0.54, 1.19)

0.27

120 (2.0)

106 (1.8)

1.14 (0.88, 1.47)

0.33

Fever/Infection2, n (%)

54 (0.9)

46 (0.8)

1.18 (0.80, 1.73)

0.42

Other2, n (%)

57 (1.0)

57 (1.0)

1.00 (0.70, 1.44)

0.99

Participants with at least one SAE, n
(%)
At least one other SAE, n (%)
3A Maternal Events

N (%)

prior to delivery2, n (%)
Hypertension admission/Medical visit
prior to delivery3, n (%)

3B Fetal/Infant Events
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pEvents

Aspirin

Placebo

RR (95% CI)1
Value1

Fetal loss after 20 weeks, n (%)

142 (2.4)

162 (2.7)

0.88 (0.70, 1.09)

0.25

Neonatal death, n (%)

163 (2.7)

190 (3.2)

0.86 (0.70, 1.05)

0.14

Miscarriage/Abortion/MTP (medical

51 (0.9)

54 (0.9)

0.95 (0.65, 1.38)

0.77

Other fetal anomaly2, n (%)

32 (0.5)

36 (0.6)

0.89 (0.55, 1.43)

0.63

Gastroschisis2, n (%)

2 (0.0)

1 (0.0)

2.01 (0.18,

0.60

termination of pregnancy), n (%)

22.11)

Note: The denominator for each serious adverse event is any participant included in the safety
population and the numerator is participants with at least one SAE form indicating the specified serious
adverse event.
1

P-values for treatment by site interaction obtained from binomial models with a log link adjusting for
site, treatment and site by treatment interaction, If treatment by site interaction term is significant (p <
0.05), then the relative risk and p-value are obtained from a binomial model with a log link adjusting for
site, treatment and site by treatment interaction and is based on the average effect across sites. If the
interaction term is not significant then the relative risk and p-value are obtained from a binomial model
with a log link adjusting for site and treatment.
2

Serious adverse events with cell counts of zero for at least one site and treatment combination. For
these SAEs the relative risks and p-values are from models adjusting for site and treatment.
3

Serious adverse events with cell counts of zero for many sites so the models did not converge.
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Definitions of Secondary outcomes
Hypertensive
disorders

Any of the following are included as evidence of hypertensive disease:
o
Any reported SAE of preeclampsia or eclampsia.
o
MNH registry report of hypertensive disease, preeclampsia or eclampsia.
o
Reports of elevated blood pressures that meet criteria based on the ACOG
2013 “Hypertension in Pregnancy” Task Force Report at any point after 20 weeks
GA.
The only case that will programmatically qualify for evidence of hypertension is:
Any individual with 2 consecutive timepoints with ≥140 mm Hg systolic or ≥90 mm
Hg diastolic where those timepoints occur more than a week (7 days) apart. The
criteria (e.g. elevated systolic or elevated diastolic) must be consistent for the two
consecutive visits.

Small for
gestational age
Perinatal mortality

For individuals that do meet the above criteria:
o If they have less no reports of elevated blood pressure or a single report of
elevated blood pressure that is followed by a normal value, they will not be
considered to have evidence of hypertensive disease.
o If they have any other reports of elevated blood pressure, their outcome
classification were adjudicated in a masked manner by clinical experts.
Defined is any newborn with weight below the 10th percentile for gestational age.
Note that growth curves are based on Intergrowth standards to define the
expected gestational age distribution for each site.
This include stillbirths and deaths in the first week of life; the perinatal period
commences at 20 completed weeks (154 days) of gestation and ends seven
completed days after birth. Pregnancies terminated prior to 20 completed weeks
of gestation are treated as missing for this outcome.

Postpartum
hemorrhage
Maternal mortality
through 42 days

Bleeding during pregnancy (i.e., the WHO generally defines as ‘light’ or ‘heavy’
bleeding based on clinical symptoms) based on self-report during the bi-weekly
visits during the study period.
Bleeding from the genital tract at any time after the 22nd week of pregnancy and
before the birth of the baby. There are two main causes of antepartum
hemorrhage, placenta previa and abruption placentae.” This outcome will be
defined based on Question A8b from Form MN02 from the MNH Registry. The
event is defined as follows in the MNH Registry Manual of Operations: “Defined as
blood loss of > 1000 cc of blood prior to delivery.”
Blood loss of 1000 ml or more from the genital tract after delivery and up to six
weeks post-delivery.
The death of a woman during pregnancy (i.e. conception to delivery) and the
puerperium (i.e. up to 42 days after delivery).

Late abortion

Spontaneous fetal loss ≥ 16 weeks and prior to 20 weeks gestation (or <500 g).

Preterm and
hypertensive
disorders

Live birth or stillbirth before 34 0/7 weeks of pregnancy are completed and those
with any evidence of hypertensive disorder

Vaginal bleeding

Antepartum
hemorrhage
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Fetal loss

Any death of an infant greater than 16 weeks GA and prior to 7 days post-delivery.
Any fetal loss (including termination of pregnancy or miscarriage) that occurs prior
to 16 weeks will be excluded.
Spontaneous
Premature expulsion of a non-viable fetus from the uterus at < 20 weeks
abortion
gestation.
Stillbirth (macerated Death of an infant prior to delivery, for a pregnancy that occurs at 20 weeks
excluded)
gestational age or greater; including only non-macerated still birth or stillbirths with
maceration status unknown.
All Stillbirth
Death of an infant which occurs prior delivery, for a pregnancy that occurs at 20
weeks gestation or greater
Medical termination An operation or other procedure to terminate pregnancy before the fetus is viable.
of pregnancy
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Statistical Plan Definitions
Safety (SAF) Population
The safety population comprises all randomized participants who received any study treatment
grouped by actual treatment received, irrespective of amount or duration of treatment received.
Modified Intention to Treat (mITT) Population
The primary analysis population is the modified intention to treat population, which includes all
eligible randomized participants who provided any post-baseline outcome data and who
delivered at 20 weeks gestational age or greater. All participants were assigned to the arm to
which they were randomized irrespective of treatment received. This population is also used for
many of the secondary analyses. Note that this population represents a change from the
protocol, which indicates that the ITT population will be used for the primary analyses.
Intention to Treat (ITT) Population
The intention to treat population includes all eligible, randomized participants. All participants
were assigned to the arm to which they were randomized irrespective of treatment received.
This population will be used to conduct sensitivity analyses for the primary outcome and will be
used as the main population for some secondary analyses.
Per Protocol (PP) Population
This population excludes all or part of the data obtained from any eligible, randomized
participants who deliver at 20 weeks gestational age or greater that did not receive at least 90%
of the full amount of intended randomized study therapy or are considered to have substantially
deviated from the protocol in a manner that may impact study outcome or treatment receipt.
The population also excludes individuals who were randomized after 10 weeks, 6 days
gestational age. Participants are grouped by actual treatment received. Treatment receipt
reasons for exclusion and substantial deviations include:
•

Documented receipt of aspirin while on study outside of assigned study drug as
identified by a reported protocol deviation

•

Not receiving treatment after randomization

•

Receipt of less than 90% of planned total doses after randomization where the number
of planned doses will be calculated as those expected between randomization and the
earliest of end of pregnancy and 36 0/7 weeks GA irrespective of if study drug
administration was prematurely discontinued for any reason prior to that point

For all analysis populations, data were analyzed as available with no imputation for missing
outcomes except where specified for sensitivity analyses.
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Drug Potency and Stability Information: Summary of stability analytical reports
Morepen Laboratories Ltd. - Parwanoo
Summary of Stability Analytical Reports
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH)
Lot: 1 (1)
Free
Assay
Mfg. date: Appearance Identification Dissolution
Salicylic Acid
(%)
09/2015
(%)
6 months
Complies
Complies
Complies
1.27
100.59
12 months
Complies
Complies
Complies
1.59
99.85
18 months
Complies
Complies
Complies
1.93
98.79
24 months
Complies
Complies
Complies
2.12
98.23
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results
not presented here.
Remarks: The sample is tested and found in compliance with the specification for the
parameters tested under stability program.
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH)
Lot: 2
Free
Assay
Mfg. date: Appearance Identification Dissolution
Salicylic
(%)
12/2016
Acid (%)
6 months
Complies
Complies
Complies
0.19
98.44
12 months
Complies
Complies
Complies
0.27
97.03
18 months
Complies
Complies
Complies
0.34
96.55
24 months
Complies
Complies
Complies
0.43
96.05
0
o
Note: Accelerated studies (40 C ± 2 C / RH 75% ± 5% RH) were also performed but results
not presented here.
Remarks: The sample is tested and found in compliance with the specification for the
parameters tested under stability program.
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH)
Lot: 3
Free
Assay
Mfg. date: Appearance Identification Dissolution
Salicylic
(%)
10/2017
Acid (%)
6 months
Complies
Complies
Complies
0.14
101.32
12 months
Complies
Complies
Complies
0.39
100.26
18 months
Complies
Complies
Complies
0.76
99.10
24 months
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results
not presented here.
Remarks: The sample is tested and found in compliance with the specification for the
parameters tested under stability program.
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HELIX Pharma (Pvt.) Ltd. Quality Control Department
Summary of Stability Analytical Reports
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH)
Lot: 1
Mfg. date: Appearance Identification Disintegration Dissolution
11/2016

Free
Salicylic
Acid
(%)
0.78
1.21

Assay
(%)

6 months
Complies
Positive
Complies
Complies
98.15
12
Complies
Positive
Complies
Complies
99.47
months
18
Complies
Positive
Complies
Complies
1.36
98.43
months
24
Complies
Positive
Complies
Complies
1.38
98.14
months
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results
not presented here.
Discussion: The 24 months stability reveals that all parameters are with in shelf life
specification and no significant changes has been observed. Hence the stability at 300C ± 20C
/ RH 65% ± 5% RH and 400C ± 2oC / RH 75% ± 5% RH is satisfactory.
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH)
Lot: 2
Mfg. date: Appearance Identification Disintegration Dissolution
08/2017

Free
Salicylic
Acid
(%)
0.96
1.07

Assay
(%)

6 months
Complies
Positive
Complies
Complies
101.69
12
Complies
Positive
Complies
Complies
101.03
months
18
Complies
Positive
Complies
Complies
0.98
100.95
months
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results
not presented here.
Discussion: The 24 months stability reveals that all parameters are with in shelf life
specification and no significant changes has been observed. Hence the stability at 300C ± 20C
/ RH 65% ± 5% RH and 400C ± 2oC / RH 75% ± 5% RH is satisfactory.
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Sensitivity Analyses for Primary Outcome
Preterm delivery, n/N (%)
Analysis with inverse probability weighting1

Aspirin

Placebo

p-Value

RR (95% CI)

-

-

<0.001

0.88 (0.82,
0.94)

ITT Population with multiple imputation2

-

-

-

0.87 (0.78,
0.96)

Per-Protocol Population3

537/4,927 (10.9) 600/4,861 (12.3)

0.020

0.89 (0.80,
0.99)

1

Relative risks, 95% confidence intervals and p-values are obtained from a binomial model with a log link
adjusting for site, treatment and site by treatment interaction with inverse probability weighting. Includes
negative outcomes for pregnancies excluded from primary analysis due to pregnancy outcome < 20
weeks (n=350), medically terminated pregnancy ≥20 weeks (n=5), or otherwise missing outcomes ≥20
weeks (n=9).
2
Relative risks and 95% confidence intervals are obtained from a binomial model with a log link adjusting
for site, treatment and site by treatment interaction for all randomized population with preterm status
determined by gestational age for all pregnancies and multiple imputation for pregnancies with missing
gestational age (n=45).
3
P-values from Cochran-Mantel-Haenszel tests stratified by site. Relative risk and 95% confidence
interval are obtained from a binomial model with a log link adjusting for site and treatment.
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